Edwards' Lifesciences earns FDA approval for heart valve: 3 things to know

The Food and Drug Administration on July 5 approved Edwards Lifesciences Corp.'s Inspiris Resilia aortic valve.

Here are three things to know.

1. The valve is intended for use in surgical aortic valve replacement.
   
   

2. The implant features anticalcification tissue properties, an expandable frame and capabilities for future valve-in-valve procedures.
   
   

3. Edwards' Lifesciences will launch the heart valve in early 2018.
   
   

More articles on supply chain:

Precision benchmarking a panacea for purchased services savings
Vertex Pharma makes 1st price hike on cystic fibrosis drug
Novo Nordisk recalls insulin pen cartridge holders